Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BenevolentAI Limited
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.
Deal Snapshot: Two years into a three-year partnership with Lilly, Verge announced another deal, with AstraZeneca’s Alexion, just months after acquiring bragging rights with early clinical data for an AI-discovered product candidate.
Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.
- Artificial Intelligence
- Drug Discovery Tools
- Other Names / Subsidiaries
- BenevolentBio, BenevolentTech
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.